BEVERLY SANG: Open Payments
NPI 1376244277 · MELISSA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$421 in 16 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $20 · 2025 $421
Food & beverage: $421
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $151 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 1 | $41 |
| Janssen Pharmaceuticals, Inc | 2 | $32 |
| ABBVIE INC. | 1 | $31 |
Products named: TRINTELLIX, Auvelity, CAPLYTA, REXULTI, UZEDY, SPRAVATO, VRAYLAR.
Industry payments across TX — which companies pay providers there.
